Evolution of the Therapeutic Care in Ovarian Cancer From 2011

Conditions

Ovarian Cancer

Keywords

ovarian cancer, observational study, survival, real world data, real life setting

Brief summary

The ESME Ovarian Cancer database is a multi-center real life database using a retrospective data collection process in 18 French Comprehensive Cancer Center (FCCC) over 20 sites). This database compiles data from existing data available from patient's electronic medical records (EMR).

Detailed description

This database compiles data from existing data available from patient's electronic medical records (EMR) and integrates data from non-structured ans structured sources. The database includes data related to patient demographics, tumor characteristics (diagnosis, histology, relapses, metastatic disease, etc.), treatments (dates, INN, route of administration, treatment protocols, reason for termination, etc.), and clinical events. Data is collected at each participating site by technicians who are specifically trained for the project using an electronic data collection (eDC) tool. Data imported into the final database are controlled, recoded, and harmonized before import according to the data management plan. All coding procedures are predefined by the data manager. There is no transmission of individual data; all data are centralized within each center using a shared anonymous format. All data is exclusively obtained retrospectively; no attempts are made to recover non available data from the patient's medical record by contacting healthcare providers or patients. ESME OC database aims to be a clinical and therapeutic database centralizing existing and available data from different sources used in the participating hospitals. Data do not contain any personal data on patients. In compliance with the authorization delivered by the French Data Protection agency to Unicancer, only aggregated statistical reports and publication are released.

Papazyan T, Martin E, Pautier P, Guerin-Charbonnel C, Rowinski E, Lecuru F, Joly F, De La Motte Rouge T, Guillemet C, Costaz H, Sabatier R, Barranger E, Colombo PE, Marchal F, Pomel C, Savoye AM, Bosquet L, Ray-Coquard I, Gladieff L, Loaec C, Frenel JS.

2025-11-14

10.1016/j.ijgc.2025.102804

PARP inhibitors as maintenance therapy in ovarian cancer after platinum-sensitive recurrence: real-world experience from the Unicancer network

Nicolas Rippstein, Christophe Zemmour, Manuel Rodrigues, Isabelle Ray‐Coquard, Laurence Gladieff et al. (18 authors)

The Oncologist2025-05-011 citations

10.1093/oncolo/oyaf075

Tumor-intrinsic chemosensitivity assessed by KELIM and prognosis by BRCA status in patients with advanced ovarian carcinomas.

Becker O, Durand A, Chevrier M, Collet L, Gladieff L, Joly F, Sauterey B, Pomel C, Costaz H, Pautier P, Guillemet C, Rouge TM, Sabatier R, Classe JM, Petit T, Leblanc E, Marchal F, Colombo PE, Barranger E, Savoye AM, Bosquet L, Ray-Coquard I, Carton M, Colomban O, You B, Rodrigues M.

2025-04-191 citations

10.1136/ijgc-2024-005815

2022-RA-858-ESGO Benefit of bevacizumab according to CA125 decline kinetic in first-line high grade serous ovarian carcinoma (HGSOC) patients in real-life setting

Ondine Becker, Marion Chevrier, Laurence Gladieff, Florence Joly, Philippe Toussaint et al. (20 authors)

Ovarian cancer2022-10-01

10.1136/ijgc-2022-esgo.576

ODALIE Study, a retrospective analysis of a real-life cohort of patients with <i>de novo</i> advanced high grade epithelial ovarian cancer treated with a first-line platinum- and taxane-based chemotherapy combined with bevacizumab.

Sarah Lagarde Bétrian, F. Penault Llorca, Patricia Pautier, Florence Joly, Isabelle Laure Ray-Coquard et al. (16 authors)

Journal of Clinical Oncology2022-06-01

10.1200/jco.2022.40.16_suppl.e17577

EP967 Natural history of patients with BRCA-mutated high grade epithelial ovarian cancer (HGEOC) before the era of PARP inhibitors maintenance in 1st line treatment

Clémence Romeo, Pierre Méeus, Manuel Rodrigues, Éric Leblanc, Anne Floquet et al. (24 authors)

2019-11-013 citations

10.1136/ijgc-2019-esgo.1013

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

No

Inclusion criteria

: * 18 years old female * Female who received surgery, chemotherapy, targeted therapy, immunotherapy, radiation therapy, diagnostic procedure, other specific therapeutic procedure) for ovarian cancer in a French Comprehensive Cancer Center.

Exclusion criteria

: None

Design outcomes

Primary

Measure	Time frame	Description
Describe the evolution of therapeutic care in ovarian cancer across the French comprehensive cancer centers	baseline	Patient characteristics, tumor characteristics and treatment patterns

Secondary

Measure	Time frame	Description
Describe the impact of therapeutic strategies on survival criteria	From date of diagnosis or first treatment until the date of date of death from any cause. Follow up until 2022.	Overall survival

Countries

France

Outcome results